




Life is interactIOn

Our proprietary Odysseion™ platform unlocks the power of integrated biophysics to resolve the trade-off between fidelity and precision

Cell-based systems

Reproduce biology with fidelity but inherently disconnected from the target



Cell-free systems

Tune to precise interactions, but isolation compromises fidelity




OMass
THERAPEUTICS




1. Extract with **fidelity**
2. Measure with **precision**
3. **Design** with intention

OMass' platform effectively attenuates biological "noise"...

... but maintains the fidelity of the native target ecosystem



...with a pipeline in immunology and rare disease, exemplified by MC2 antagonist entering the clinic next year



World-class team

Experienced Leadership



Ros Deegan Bicycle
CEO  



Steven Charlton
CSO  



Melissa Faris  
CBO



Hsin Loke  
COO and SVP Finance

Seasoned drug hunters





Jon Roffey  
SVP Discovery and Non-clinical Development



Jonathan Hopper
VP Platforms 




Winfried Barchet  
VP Translational Biology



Steve Griffen   
VP Clinical Development

Technology pioneers



Professor Carol Robinson
Scientific Advisor 



Idi Liko 
Snr Director of Mass Spec